PCM
UTHR icon

Prelude Capital Management’s United Therapeutics UTHR Stock Holding History

Prelude Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.39M Sell
2,345
-1,415
-38% -$705K 0.11% 230
2025
Q4 		$1.83M Buy
3,760
+946
+34% +$441K 0.13% 167
2025
Q3 		$1.18M Buy
+2,814
New +$946K 0.09% 276
2023
Q4 		– Sell
-6,415
Closed -$1.45M – 1359
2023
Q3 		$1.45M Buy
+6,415
New +$1.48M 0.09% 244
2021
Q3 		– Sell
-33,635
Closed -$6.03M – 2037
2021
Q2 		$6.03M Buy
33,635
+11,160
+50% +$2.13M 0.18% 76
2021
Q1 		$3.76M Buy
22,475
+615
+3% +$103K 0.1% 148
2020
Q4 		$3.32M Buy
21,860
+20,998
+2,436% +$2.76M 0.08% 175
2020
Q3 		$87K Sell
862
-3,318
-79% -$364K ﹤0.01% 959
2020
Q2 		$506K Buy
+4,180
New +$470K 0.03% 474
2019
Q3 		– Sell
-222
Closed -$17K – 2063
2019
Q2 		$17K Buy
+222
New +$20.8K ﹤0.01% 1318
2017
Q4 		– Sell
-2,406
Closed -$282K – 1739
2017
Q3 		$282K Buy
+2,406
New +$307K 0.03% 535
2017
Q1 		– Sell
-2,888
Closed -$414K – 1791
2016
Q4 		$414K Buy
+2,888
New +$369K 0.05% 353
2016
Q3 		– Sell
-1,981
Closed -$210K – 1832
2016
Q2 		$210K Sell
1,981
-4,504
-69% -$502K 0.03% 480
2016
Q1 		$723K Sell
6,485
-708
-10% -$89.6K 0.1% 222
2015
Q4 		$1.13M Buy
7,193
+4,345
+153% +$633K 0.17% 143
2015
Q3 		$374K Sell
2,848
-559
-16% -$89.7K 0.05% 356
2015
Q2 		$593K Sell
3,407
-640
-16% -$115K 0.08% 274
2015
Q1 		$698K Sell
4,047
-334
-8% -$50.9K 0.1% 254
2014
Q4 		$567K Sell
4,381
-1,927
-31% -$248K 0.08% 275
2014
Q3 		$812K Buy
6,308
+674
+12% +$69.5K 0.11% 218
2014
Q2 		$499K Sell
5,634
-2,098
-27% -$202K 0.07% 381
2014
Q1 		$727K Buy
7,732
+1,856
+32% +$190K 0.1% 282
2013
Q4 		$664K Buy
5,876
+1,780
+43% +$161K 0.11% 259
2013
Q3 		$323K Sell
4,096
-8,257
-67% -$604K 0.05% 398
2013
Q2 		$813K Buy
+12,353
New +$796K 0.17% 139

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Prelude Capital Management's UTHR Position: Q1 2026 in Review

Prelude Capital Management reduced its United Therapeutics (UTHR) stake by 38% in Q1 2026, selling an estimated $705K and leaving 2,345 shares worth $1.39M. The position accounts for 0.11% of the portfolio, ranked #230.

Prelude Capital Management first reported a position in UTHR in Q2 2013 and has held it in 25 quarters since. The position peaked at $6.03M in Q2 2021. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Prelude Capital Management held 2,345 shares of United Therapeutics worth $1.39M as of Q1 2026.
  • Prelude Capital Management sold 1,415 United Therapeutics shares in Q1 2026, an estimated $705K.
  • United Therapeutics made up 0.11% of Prelude Capital Management's portfolio in Q1 2026, its #230 holding.
  • Prelude Capital Management first reported a position in United Therapeutics in Q2 2013 and has held it in 25 quarters since.
  • Prelude Capital Management's United Therapeutics position peaked at $6.03M in Q2 2021.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.